

To the press and whom it may concern,

**Nanotis, a UTokyo-affiliated startup, receives funding from Taisho
Pharmaceutical for R&D of rapid diagnostic devices**

Nanotis (Head Office: Shibuya, Tokyo; CEO, Founder: Lisa Sakashita), a University of Tokyo-affiliated startup that is developing rapid diagnostic devices for infectious diseases such as influenza, has received funding from Taisho Pharmaceutical Co., Ltd. (Head Office: Toshima, Tokyo; CEO: Shigeru Uehara) in its pre-series A funding round.



**Provide all people who combat diseases
with a rapid and accurate diagnosis**



Nanotis, which was established in June 2016, is a startup company affiliated with the University of Tokyo. Our corporate mission is to “Provide all people who combat diseases with a rapid and accurate diagnosis.” Thus far, we have been developing next-generation rapid diagnostic devices. The first target for our devices is influenza, and we aim to realize high-sensitivity rapid diagnostic tests that do not require specialized technology to meet the clinical environment’s needs.

In order to prevent the spread of infectious diseases, it is important to conduct early examinations and perform prompt actions, such as the treatment and isolation of patients. The current COVID-19 pandemic has served as a reminder of the importance of quick, easy, and highly sensitive screening tests. Nanotis is developing a platform technology that can be applied to various fields, such as infectious diseases other than influenza and food inspection. In the future, we plan to promote the construction of an innovative healthcare system aiming at primary screening tests at non-medical institutions such as private homes, cooperation with telemedicine, and application to global-scale epidemiological surveys.

Taisho Pharmaceutical has strengths in both the self-medication and prescription pharmaceutical businesses. With its investment, we will further expand our business by promoting R&D to establish

underlying technologies and strengthening the recruitment of core personnel, like engineers and management personnel.

These are the first funds raised in the pre-series A round. We will continue to raise funds from institutional and individual investors.

■ Corporate Profile

Company Name: Nanotis Corporation

CEO: Lisa Sakashita

Address: 5-50-13 Yoyogi, Shibuya, Tokyo, 151-0053, Japan

Laboratory: The University of Tokyo, Engineering Building 4, 7-3-1 Hongo, Bunkyo, Tokyo, 113-8656, Japan

Established: June 6, 2016

Capital Stock: ¥ 88,157,660

Business description: Research and development of rapid diagnostic devices

URL: <http://nanotis.net/>